“…Furthermore, the treatment of aged O. degus with ANDRO has shown protection from several aspects of AD-pathogenesis: i.e., decreased Aβ accumulation and lower tau phosphorylation, recovery of synaptic protein loss and cognitive impairment ( Serrano et al, 2014 ; Rivera et al, 2016 ). Moreover, several studies using ANDRO treatments had reported other effects such as adult neurogenesis ( Varela-Nallar et al, 2016 ), neurite out-growth ( Xu et al, 2019 ), and neuroprotection ( Lindsay et al, 2020 ), along with decreased neuroinflammation, oxidative stress, and synaptic dysfunction in aged animals ( Serrano et al, 2014 ; Lu et al, 2019 ; Zolezzi and Inestrosa, 2019 ; Lindsay et al, 2020 ). Specifically, ANDRO activates Wnt signaling pathway by inhibiting directly GSK-3β ( Tapia-Rojas et al, 2015 ), but also it has been described as a modulator of other cellular signaling including the BACE1-dependent amyloid processing, the Nrf2-mediated p62, the Keap1/Nrf2/ARE/HO-1, the PI3K-Akt, and the NF-kB pathways ( Seo et al, 2017 ; Gu et al, 2018 , 2019 ; Panche et al, 2019 ).…”